Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1

Isabel Freund1,2, Stephanie Hehlgans1, Daniel Martin1

  • 1Department of Radiotherapy and Oncology, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.

Cells
|May 21, 2020
PubMed

Insights

NIMA (never-in-mitosis gene A)-related kinase 1 (Nek1) knockdown sensitizes cancer cells to radiation therapy and may serve as a predictive biomarker for treatment response in cervical cancer patients. Targeting Nek1 could improve radiation therapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiation Oncology

Background:

  • NIMA (never-in-mitosis gene A)-related kinase 1 (Nek1) influences DNA repair, cell cycle checkpoints, and apoptosis.
  • The potential of Nek1 as a molecular target for enhancing radiation sensitivity in malignant cells is not well understood.

Purpose of the Study:

  • To investigate the role of Nek1 in cellular response to ionizing radiation.
  • To evaluate Nek1 as a potential biomarker for predicting treatment outcomes in cervical cancer.

Main Methods:

  • Utilized doxycycline-inducible Nek1 shRNA in HeLa and siRNA in HCT-15 cells for knockdown studies.
  • Assessed radiosensitivity, DNA damage, cell cycle, and apoptosis in vitro.
  • Conducted preclinical studies in NSG mice xenograft models of cervical cancer.
  • Correlated Nek1 expression in patient biopsies with clinical data and TCGA cohort.

Main Results:

  • Nek1 knockdown (KD) sensitized both cell lines to ionizing radiation, particularly with fractionated doses.
  • Nek1 KD combined with fractionated radiation showed a significant cytostatic effect in preclinical cervical cancer models.
  • Elevated Nek1 expression in cervical cancer patients correlated with increased treatment failure and reduced survival.
  • TCGA data validated the association between high Nek1 expression and decreased disease-free survival.

Conclusions:

  • Nek1 plays a crucial role in cellular response to radiation therapy.
  • Nek1 is a potential predictive biomarker for radiation therapy response in cervical cancer.
  • Targeting Nek1 may offer a therapeutic strategy to improve outcomes with optimized radiation fractionation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
444
Nucleotide Excision Repair01:08

Nucleotide Excision Repair

Overview
40.4K